Health
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial – The Lancet
Taking safety, immunogenicity, and production capacity into account, the 3 μg doseof CoronaVac is the suggested dose for efficacy assessment in future phase 3 trials….
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions
Continue Reading
-
Noosa News22 hours agoMeet Chad Burgess, Pauline Hanson’s One Nation Party
-
Noosa News22 hours agoWestern Queensland graziers begin grim stock count after catastrophic floods
-
General21 hours agoTyler Wright soaks up Bells Beach return as poor conditions at Rip Curl Pro sees men’s opening round called off
-
General21 hours agoTruck driver charged with causing death by dangerous driving after highway crash